Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 16 · below the Ichimoku cloud · RSI 8 (oversold) · MACD above its signal · at its 52-week high
| 4.01 | 52-week high | +0.50% |
| 4.00 | Previous month high | +0.25% |
| 3.99 | R3 (classic) | +0.00% |
| 3.99 | R2 (classic) | +0.00% |
| 3.99 | R1 (classic) | +0.00% |
| 3.99 | Pivot | +0.00% |
| 3.99 | S1 (classic) | +0.00% |
| 3.99 | S2 (classic) | +0.00% |
| 3.99 | S3 (classic) | +0.00% |
| 3.99 | Previous day high | +0.00% |
| 3.99 | Previous day low | +0.00% |
| 3.99 | Previous week high | +0.00% |
| 3.99 | Previous week low | +0.00% |
| 3.99 | Previous month low | +0.00% |
| 3.99 | Price now | |
| 3.20 | 52-week low | −19.80% |
None of the 29 investors followed here reported a position in RTGN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RTGN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for RTGN.
TimeframesUp on the weekly, down on the hourly and daily, mixed on the monthly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
over a rising 21 EMA, 21 over 50
bouncing over the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 25.0 | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 | +24.7% | ||
| 2025 | 25.6 | 0.0 | 0.0 | 149.8 | 0.0 | 0.0 | -29.5 | 0.0 | 0.0 | 0.3 | -9.9 | 0.0 | +100.0% |
| 2024 | 0.3 | 12.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -54.3 | 0.0 | −48.2% |
| 2023 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.1 | 0.0 | -31.2 | 0.0 | −65.7% |
| 2022 | 0.0 | 0.0 | 0.0 | 66.7 | 43.0 | 11.9 | 150.0 | -52.5 | -5.3 | 0.0 | +200.0% |
No analyst coverage for this instrument.
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
No recent headlines.